Table 1. Significant inhibitors of all three cohesin-deficient clones.
Table 1—source data 1. Compounds with growth inhibitory activity (AOC) ranked to produce Table 1.
elife-61405-table1-data1.xlsx (61.6KB, xlsx)
Table 1—source data 2. Compounds effective in the secondary screen ranked to produce Table 1.
elife-61405-table1-data2.xlsx (10.6KB, xlsx)
| Compound | Rank 1° screen | Rank 2° screen | Target | Pathway | 1° differential AOC activity | ||
|---|---|---|---|---|---|---|---|
| RAD21+/- | SMC3+/- | STAG2-/- | |||||
| WAY-600 | 1 | 3 | mTORC1/2 | PI3K/AKT/mTOR | 0.30 | 0.37 | 0.32 |
| I-BET-762 | 2 | 8 | BET proteins | Epigenetics | 0.25 | 0.27 | 0.29 |
| LY2090314 | 3 | 6 | GSK3 | WNT | 0.25 | 0.22 | 0.25 |
| Vistusertib (AZD2014) | 4 | 1 | mTORC1/2 | PI3K/AKT/mTOR | 0.18 | 0.33 | 0.26 |
| P276-00 | 5 | 17 | CDK1/4/9 | Cell Cycle | 0.17 | 0.29 | 0.28 |
| MK-8745 | 6 | 22 | Aurora A | Cell Cycle | 0.18 | 0.30 | 0.26 |
| Ethacridine lactate | 7 | 28 | Anti-infection | Microbiology | 0.18 | 0.25 | 0.27 |
| CUDC-101 | 8 | 36 | EGFR, HDAC, HER2 | Epigenetics | 0.16 | 0.25 | 0.24 |
| Dabrafenib (GSK2118436) | 9 | 9 | BRAF | MAPK | 0.18 | 0.27 | 0.18 |
| SAR131675 | 10 | 34 | VEGFR3 | Protein Tyrosine Kinase | 0.15 | 0.17 | 0.33 |
| ZM 447439 | 11 | 41 | Aurora A/B | Cell Cycle | 0.16 | 0.22 | 0.24 |
| Gitoxigenin Diacetate | 12 | 32 | NA | Other | 0.17 | 0.24 | 0.20 |
| UNC669 | 13 | 62 | Epigenetic Reader Domain | Epigenetics | 0.18 | 0.23 | 0.20 |
| 4-Phenylbutyric Acid | 14 | 29 | Endoplasmic reticulum stress | Other | 0.20 | 0.17 | 0.20 |
| Ipatasertib (GDC-0068) | 15 | 12 | AKT | PI3K/AKT/mTOR | 0.21 | 0.19 | 0.16 |
| VX-702 | 16 | 43 | P38 MAPK | MAPK | 0.15 | 0.19 | 0.21 |
| RVX-208 | 17 | 58 | BET proteins | Epigenetics | 0.16 | 0.20 | 0.17 |
| Dihydroergotamine mesylate | 18 | 49 | NA | Other | 0.16 | 0.19 | 0.16 |
| Olaparib | 351 | PARP1/2 | DNA Damage | 0.11 | 0.13 | 0.22 | |